These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10419558

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).
    Williams GC, Liu A, Knipp G, Sinko PJ.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3456-62. PubMed ID: 12384350
    [Abstract] [Full Text] [Related]

  • 24. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
    Berginc K, Trontelj J, Kristl A.
    Drug Metab Pharmacokinet; 2010 Nov; 25(3):307-13. PubMed ID: 20610890
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
    Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ.
    AIDS; 2001 Jul 27; 15(11):1353-8. PubMed ID: 11504956
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
    Kim AE, Dintaman JM, Waddell DS, Silverman JA.
    J Pharmacol Exp Ther; 1998 Sep 27; 286(3):1439-45. PubMed ID: 9732409
    [Abstract] [Full Text] [Related]

  • 30. Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.
    Patel J, Pal D, Vangal V, Gandhi M, Mitra AL.
    Pharm Res; 2002 Nov 27; 19(11):1696-703. PubMed ID: 12458676
    [Abstract] [Full Text] [Related]

  • 31. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
    Antimicrob Agents Chemother; 2004 Jul 27; 48(7):2388-93. PubMed ID: 15215085
    [Abstract] [Full Text] [Related]

  • 32. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
    Ronaldson PT, Lee G, Dallas S, Bendayan R.
    Pharm Res; 2004 May 27; 21(5):811-8. PubMed ID: 15180339
    [Abstract] [Full Text] [Related]

  • 33. Xenobiotic efflux pumps in isolated fish brain capillaries.
    Miller DS, Graeff C, Droulle L, Fricker S, Fricker G.
    Am J Physiol Regul Integr Comp Physiol; 2002 Jan 27; 282(1):R191-8. PubMed ID: 11742838
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM.
    Clin Pharmacol Ther; 1998 Apr 27; 63(4):453-64. PubMed ID: 9585800
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
    Dupuis ML, Flego M, Molinari A, Cianfriglia M.
    HIV Med; 2003 Oct 27; 4(4):338-45. PubMed ID: 14525546
    [Abstract] [Full Text] [Related]

  • 38. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
    Richter M, Gyémánt N, Molnár J, Hilgeroth A.
    Pharm Res; 2004 Oct 27; 21(10):1862-6. PubMed ID: 15553233
    [Abstract] [Full Text] [Related]

  • 39. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.
    Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T.
    Antimicrob Agents Chemother; 2004 Mar 27; 48(3):809-14. PubMed ID: 14982769
    [Abstract] [Full Text] [Related]

  • 40. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.
    Antimicrob Agents Chemother; 2004 Nov 27; 48(11):4256-62. PubMed ID: 15504850
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.